|
The ISET Test (Isolation by Size of Tumor cells / Trophoblastic cells) is a diagnostic blood test that detects circulating tumor cells in a blood sample.〔("ISET : une prise de sang précoce pour dépister des maladies génétiques'' ) par Inserm dans ''Futura Santé'' du 13 décembre 2012.〕〔("ISET : un test génétique prénatal à encadrer ) par Floriane Blanc dans ''Pour la science'' de novembre 2013.〕〔("Cancer : une nouvelle méthode pronostique non invasive testée sur le cancer du foie" ) par INSERM dans ''Caducee.net'' du12 mai 2004.〕 The test uses an in-vitro diagnostic system developed at INSERM, the Université Paris Descartes and Assistance Publique Hôpitaux de Paris (AP-HP) in order to isolate cancer cells from blood without loss and identify them through a diagnostic cytopathology-based approach. ==Operation== A 1-ml sample of blood will typically contain 5 to 10 million leukocytes, 5 billion erythrocytes, and a small number of circulating rare cells, including: * non-tumor cells such as epithelial-normal cells, epithelial-atypical cells, endothelial vells and stem cells; * physiological state-dependent cells such as fetal cells in pregnant and ex-pregnant women; * circulating tumor cells (CTCs) which are of diagnostic value in diagnosing various cancers. The diagnostic problem is to find and identify the rare CTCs among the abundant other cells in a given blood sample. The ISET technology is based on the observation that tumor cells of all types of solid cancers are larger than blood cells (leukocytes and erythrocytes). However, blood filtration to recover rare circulating tumor cells without loss and without cell damage is a challenge. The ISET test uses a specially designed device and specially designed filters to allow the elimination of all erythrocytes and most leukocytes from the sample, making the subsequent cytopathology process significantly easier and more accurate. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「ISET Test」の詳細全文を読む スポンサード リンク
|